Antibody molecules to pd-1 and uses thereof
AssigneesNovartis AG, President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
InventorsGordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
Life of this patent
Estimating the term…
Abstract
Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
Claims30
An antibody molecule capable of binding to human Programmed Death-1 (PD-1), comprising:
- (a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO:
- 4, a VHCDR2 amino acid sequence of SEQ ID NO:
- 5, and a VHCDR3 amino acid sequence of SEQ ID NO:
- 3;
- and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO:
- 13, a VLCDR2 amino acid sequence of SEQ ID NO:
- 14, and a VLCDR3 amino acid sequence of SEQ ID NO:
- 33;
- (b) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:
- 1;
- a VHCDR2 amino acid sequence of SEQ ID NO:
- 2;
- and a VHCDR3 amino acid sequence of SEQ ID NO:
- 3;
- and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO:
- 10, a VLCDR2 amino acid sequence of SEQ ID NO:
- 11, and a VLCDR3 amino acid sequence of SEQ ID NO:
- 32;
- (c) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:
- 224, a VHCDR2 amino acid sequence of SEQ ID NO:
- 5, and a VHCDR3 amino acid sequence of SEQ ID NO:
- 3;
- and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO:
- 13, a VLCDR2 amino acid sequence of SEQ ID NO:
- 14, and a VLCDR3 amino acid sequence of SEQ ID NO:
- 33;
- or
- (d) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:
- 224;
- a VHCDR2 amino acid sequence of SEQ ID NO:
- 2;
- and a VHCDR3 amino acid sequence of SEQ ID NO:
- 3;
- and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO:
- 10, a VLCDR2 amino acid sequence of SEQ ID NO:
- 11, and a VLCDR3 amino acid sequence of SEQ ID NO:
- 32.
An antibody molecule capable of binding to human PD-1, comprising a VH comprising the amino acid sequence of SEQ ID NO:
- 38 and a VL comprising the amino acid sequence of SEQ ID NO:
- 54.
An antibody molecule capable of binding to human PD-1, comprising a VH comprising the amino acid sequence of SEQ ID NO:
- 38 and a VL comprising the amino acid sequence of SEQ ID NO:
- 70.
A bispecific antibody molecule having a first binding specificity for PD-1 and a second binding specificity for TIM-3, LAG-3, CEACAM-1, CEACAM-5, PD-L1 or PD-L2, wherein the bispecific antibody molecule comprises:
- (a) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:
- 4, a VHCDR2 amino acid sequence of SEQ ID NO:
- 5, and a VHCDR3 amino acid sequence of SEQ ID NO:
- 3;
- and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO:
- 13, a VLCDR2 amino acid sequence of SEQ ID NO:
- 14, and a VLCDR3 amino acid sequence of SEQ ID NO:
- 33;
- (b) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:
- 1;
- a VHCDR2 amino acid sequence of SEQ ID NO:
- 2;
- and a VHCDR3 amino acid sequence of SEQ ID NO:
- 3;
- and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO:
- 10, a VLCDR2 amino acid sequence of SEQ ID NO:
- 11, and a VLCDR3 amino acid sequence of SEQ ID NO:
- 32;
- (c) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:
- 224, a VHCDR2 amino acid sequence of SEQ ID NO:
- 5, and a VHCDR3 amino acid sequence of SEQ ID NO:
- 3;
- and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO:
- 13, a VLCDR2 amino acid sequence of SEQ ID NO:
- 14, and a VLCDR3 amino acid sequence of SEQ ID NO:
- 33;
- or
- (d) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:
- 224;
- a VHCDR2 amino acid sequence of SEQ ID NO:
- 2;
- and a VHCDR3 amino acid sequence of SEQ ID NO:
- 3;
- and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO:
- 10, a VLCDR2 amino acid sequence of SEQ ID NO:
- 11, and a VLCDR3 amino acid sequence of SEQ ID NO:
- 32.
Dependencies are inferred from the claim text.